Literature DB >> 18372399

Probing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243).

Xulin Xu1, Maurizio Recanatini, Marinella Roberti, Gea-Ny Tseng.   

Abstract

We studied the mechanisms and sites of activator actions of 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid [PD307243 (PD)] and 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea [NS1643 (NS)] on the human ether-a-go-go-related gene (hERG) channel expressed in oocytes and COS-7 cells. PD and NS affected hERG in a concentration-dependent manner, reaching a maximal increase in current amplitude by 100% and > or = 300% (1-s test pulse to 0 mV), with apparent K(d) values of 3 and 20 microM, respectively. Both drugs slowed hERG inactivation. NS additionally shifted the activation curve in the negative direction, accelerated activation, and slowed deactivation. Kinetic model simulations suggested that the activator effects of PD and NS could be largely accounted for by their effects on the hERG gating kinetics. Both drugs worked from outside the cell membrane but their binding sites seemed to be distinctly different. Perturbing the conformation of outer vestibule/external pore entrance (by cysteine substitution at high-impact positions or cysteine side chain modification at intermediate-impact positions) prevented the activator effect of NS but not that of PD. Furthermore, the peptide toxin BeKm-1, which bound to the outer mouth of the hERG channel, suppressed NS effect but potentiated PD effect. We propose that NS is a "gating-modifier": it binds to the outer vestibule/pore entrance of hERG and increases current amplitudes by promoting channel activation while retarding inactivation. The activator effect of PD was prevented by external quaternary ammonium cations or dofetilide, which approached the hERG selectivity filter from opposite sides of the membrane and depleted K(+) ions in the selectivity filter. We suggest that PD may work as a "pore-modifier" of the hERG channel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18372399      PMCID: PMC3888322          DOI: 10.1124/mol.108.045591

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  33 in total

1.  Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.

Authors:  Jiesheng Kang; Xiao-Liang Chen; Hongge Wang; Junzhi Ji; Hsien Cheng; Josephine Incardona; William Reynolds; Fabrice Viviani; Michel Tabart; David Rampe
Journal:  Mol Pharmacol       Date:  2004-11-17       Impact factor: 4.436

2.  Dynamic conformational changes of extracellular S5-P linkers in the hERG channel.

Authors:  Min Jiang; Mei Zhang; Innokenty V Maslennikov; Jie Liu; Dong-Mei Wu; Yuliya V Korolkova; Alexander S Arseniev; Eugene V Grishin; Gea-Ny Tseng
Journal:  J Physiol       Date:  2005-09-08       Impact factor: 5.182

3.  Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator.

Authors:  Matthew Perry; Frank B Sachse; Michael C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-10       Impact factor: 11.205

4.  Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643).

Authors:  Rie Schultz Hansen; Thomas Goldin Diness; Torsten Christ; Joachim Demnitz; Ursula Ravens; Søren-Peter Olesen; Morten Grunnet
Journal:  Mol Pharmacol       Date:  2005-10-11       Impact factor: 4.436

5.  Mechanism of action of a novel human ether-a-go-go-related gene channel activator.

Authors:  Oscar Casis; Søren-Peter Olesen; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2005-11-11       Impact factor: 4.436

6.  Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.

Authors:  Jun Zhou; Corinne E Augelli-Szafran; Jenifer A Bradley; Xian Chen; Bryan J Koci; Walter A Volberg; Zhuoqian Sun; Jason S Cordes
Journal:  Mol Pharmacol       Date:  2005-06-23       Impact factor: 4.436

7.  A cation-pi interaction between extracellular TEA and an aromatic residue in potassium channels.

Authors:  Christopher A Ahern; Amy L Eastwood; Henry A Lester; Dennis A Dougherty; Richard Horn
Journal:  J Gen Physiol       Date:  2006-12       Impact factor: 4.086

8.  Structural basis of TEA blockade in a model potassium channel.

Authors:  Michael J Lenaeus; Magdalini Vamvouka; Pamela J Focia; Adrian Gross
Journal:  Nat Struct Mol Biol       Date:  2005-04-24       Impact factor: 15.369

9.  Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling.

Authors:  Gea-Ny Tseng; Kailas D Sonawane; Yuliya V Korolkova; Mei Zhang; Jie Liu; Eugene V Grishin; H Robert Guy
Journal:  Biophys J       Date:  2007-02-09       Impact factor: 4.033

10.  Molecular determinants of HERG channel block.

Authors:  Kaichiro Kamiya; Ryoko Niwa; John S Mitcheson; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2006-02-10       Impact factor: 4.436

View more
  15 in total

Review 1.  Revealing the structural basis of action of hERG potassium channel activators and blockers.

Authors:  Matthew Perry; Michael Sanguinetti; John Mitcheson
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

2.  Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels.

Authors:  A P Larsen; B H Bentzen; M Grunnet
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Molecular determinants of human ether-à-go-go-related gene 1 (hERG1) K+ channel activation by NS1643.

Authors:  Morten Grunnet; Jennifer Abbruzzese; Frank B Sachse; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2010-09-27       Impact factor: 4.436

4.  Modulation of Kv 11.1 (hERG) channels by 5-(((1H-indazol-5-yl)oxy)methyl)-N-(4-(trifluoromethoxy)phenyl)pyrimidin-2-amine (ITP-2), a novel small molecule activator.

Authors:  Harinath Sale; Samrat Roy; Jayakumar Warrier; Srinivasan Thangathirupathy; Yoganand Vadari; Shruthi K Gopal; Prasad Krishnamurthy; Manjunath Ramarao
Journal:  Br J Pharmacol       Date:  2017-06-18       Impact factor: 8.739

5.  Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel.

Authors:  Hongkang Zhang; Beiyan Zou; Haibo Yu; Alessandra Moretti; Xiaoying Wang; Wei Yan; Joseph J Babcock; Milena Bellin; Owen B McManus; Gordon Tomaselli; Fajun Nan; Karl-Ludwig Laugwitz; Min Li
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-28       Impact factor: 11.205

6.  Pharmacological and electrophysiological characterization of AZSMO-23, an activator of the hERG K(+) channel.

Authors:  R Mannikko; M H Bridgland-Taylor; H Pye; S Swallow; N Abi-Gerges; M J Morton; C E Pollard
Journal:  Br J Pharmacol       Date:  2015-04-10       Impact factor: 8.739

Review 7.  Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules.

Authors:  Ping-zheng Zhou; Joseph Babcock; Lian-qing Liu; Min Li; Zhao-bing Gao
Journal:  Acta Pharmacol Sin       Date:  2011-05-30       Impact factor: 6.150

8.  The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism.

Authors:  Guido Gessner; Regina Macianskiene; John G Starkus; Roland Schönherr; Stefan H Heinemann
Journal:  Eur J Pharmacol       Date:  2010-01-25       Impact factor: 4.432

9.  PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K+ conductance.

Authors:  Matthew Perry; Frank B Sachse; Jennifer Abbruzzese; Michael C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-05       Impact factor: 11.205

Review 10.  HERG1 channel agonists and cardiac arrhythmia.

Authors:  Michael C Sanguinetti
Journal:  Curr Opin Pharmacol       Date:  2013-11-27       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.